EQS-Adhoc: Biotest AG: Delisting of Biotest shares from the Frankfurt Stock Exchange with effect from 6 June 2025

 

 

Ad-hoc RELEASE

Announcement according to Article 17 European Market Abuse Regulation (MAR)

Biotest AG: Delisting of Biotest shares from the Frankfurt Stock Exchange with effect from 6 June 2025

Dreieich, 03 June 2025. The Frankfurt Stock Exchange today informed Biotest AG that it has approved the company's application to revoke the admission of Biotest shares (ordinary shares of Biotest AG: ISIN°DE0005227201, Biotest AG preference shares: ISIN DE0005227235) from trading on the regulated market of the Frankfurt Stock Exchange and in the segment of the regulated market with additional post-admission requirements (Prime Standard).

In accordance with the end of the acceptance period specified in the offer document for the public delisting offer by Grifols Biotest Holdings GmbH, the delisting will take effect at the end of 6 June 2025.

After this date, the shares of Biotest AG will no longer be traded on the Frankfurt Stock Exchange and the additional listing requirements will no longer apply.

 

Biotest Aktiengesellschaft
Board of Management

Biotest AG

Landsteinerstr. 5

D-63303 Dreieich

www.biotest.com

 

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
 

About Biotest

Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,500 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been part of the Grifols Group, Barcelona, Spain (www.grifols.com).

 

IR contact

Dr. Monika Baumann (Buttkereit)

phone: +49-6103-801-4406
email: ir@biotest.com

 

PR contact

Dirk Neumüller

phone: +49-6103-801-269
email: pr@biotest.com

 

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201

Preference shares: securities’ ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate